9月7日到13日，全球医药市场共完成了14项授权和合作协议，中国医药市场占了2项，均为出海交易。晟济药业将SJ02在中国大陆的独家商业化权益转让给欧加农，首付款1200万美元。诺纳生物/和铂医药与Umoja Biopharma达成合作，共同推进体内CAR-T细胞疗法开发。
在全球范围内，共签署了12项协议。其中最大的一项交易是赛诺菲与Orano Med和RadioMedix就二期肿瘤资产212Pb-dotamtate达成的授权交易，首付款1.08亿美元，总价值高达3.46亿美元。
Between September 7 and 13, a total of 14 licensing and collaboration deals were signed globally. In China's biotech sector, CenterGene Pharmaceuticals entered an out-licensing agreement with Organon for SJ02, securing an upfront payment of $12 million. Additionally, Harbour BioMed and Umoja BioPharma formed a partnership to develop pre-clinical CAR designs for novel drug candidates.
Globally, 12 licensing and cooperation agreements were concluded during the same week. The largest deal of the week was between Orano Med, RadioMedix, and Sanofi for the Phase II oncology asset 212Pb-dotamtate, valued at $346 million, including an upfront payment of $108 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
